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Abstract
Insulin-like growth factor binding protein 3 (IGFBP3),
which is induced by wild-type p53, regulates IGF and
interacts with the TGF-B pathway. IGFBP3 promoter
methylation may occur in colorectal cancer with or
without the CpG island methylator phenotype (CIMP),
which is associated with microsatellite instability (MSI)
and TGFBR2 mutation. We examined the relationship
between IGFBP3 methylation, p53 expression, CIMP
and MSI in 902 population-based colorectal cancers.
Utilizing real-time PCR (MethyLight), we quantified pro-
moter methylation in IGFBP3 and eight other CIMP-
high–specificpromoters (CACNA1G ,CDKN2A,CRABP1,
IGF2 , MLH1, NEUROG1, RUNX3, and SOCS1). IGFBP3
methylation was far more frequent in non–MSI-high
CIMP-high tumors (85% = 35/41) than in MSI-high CIMP-
high (49% = 44/90, P < .0001), MSI-high non–CIMP-high
(17% = 6/36, P < .0001), and non–MSI-high non–CIMP-
high tumors (22% = 152/680, P < .0001). Among CIMP-
high tumors, the inverse relationship between MSI
and IGFBP3 methylation persisted in p53-negative tu-
mors (P < .0001), but not in p53-positive tumors. IGFBP3
methylation was associated inversely with TGFBR2
mutation in MSI-high non–CIMP-high tumors (P =
.02). In conclusion, IGFBP3methylation is inversely as-
sociated with MSI in CIMP-high colorectal cancers,
and this relationship is limited to p53-negative tu-
mors. Our data suggest complex relationship between
global genomic/epigenomic phenomena (such as MSI/
CIMP), single molecular events (e.g., IGFBP3 methyl-
ation, TP53 mutation, and TGFBR2 mutation), and the
related pathways.
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Introduction
Insulin-like growth factor binding protein 3 (IGFBP3) is the main
carrier of insulin-like growth factors (IGFs) in the circulation,
where this complex regulates biologic function of IGFs [1].
IGFBP3 has been shown to regulate both cell growth and death,
independently of its interaction with IGFs [2,3]. IGFBP3 pro-
moter methylation and gene silencing are observed in human
cancers including colorectal cancer [4,5], and have been asso-
ciated with poor clinical outcome in lung and ovarian cancers
[6,7]. IGFBP3 is induced by wild-type p53 [8], and promoter meth-
ylation at the p53 regulatory element causes gene silencing
resistant to p53 [9]. IGFBP3 enhances the p53-dependent
apoptotic response of colorectal adenoma cells to DNA dam-
age [10]. IGFBP3 is known to interact with the transforming
growth factor–beta (TGF-b) pathway [11–13].
Transcriptional inactivation by cytosine methylation at pro-
moter CpG islands of tumor suppressor genes is an important
mechanism in human carcinogenesis [14]. A number of tumor
suppressor genes can be silenced by promoter methylation in
colorectal cancers [14]. A subset of colorectal cancers exhibit
widespread promoter CpG island methylation, which is re-
ferred to as the CpG island methylator phenotype (CIMP)
[15]. CIMP-high colorectal tumors have a distinct clinical, patho-
logic, and molecular profile, such as associations with prox-
imal tumor location, female, poor differentiation, BRAFmutation,
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wild-type tumor protein p53 (TP53 ), and inactive WNT/
CTNNB1 (b-catenin) [16–24], independent of microsatellite
instability (MSI) status [19–23]. In addition, CIMP-high in
microsatellite instability–high (MSI-H) colorectal cancer is
correlated with the transforming growth factor b receptor type
2 gene (TGFBR2) mononucleotide mutation [25]. Molecular
classification of colorectal cancer based on CIMP and MSI is
increasingly important [26,27] because MSI and CIMP repre-
sent global genomic and epigenomic phenomena, respec-
tively, in tumor cells, and largely determine pathologic and
molecular features of colorectal cancer [27].
In this study, using quantitative DNA methylation analysis
(MethyLight) and a large number of population-based colo-
rectal cancers, we have examined the relationship between
IGFBP3 promoter methylation and various molecular fea-
tures in colorectal cancer, including MSI, CIMP, p53, and mu-
tations in TGFBR2 and BCL2-associated X protein (BAX).
Discovering molecular correlates is important in cancer
research, because it may: 1) provide clues to pathogenesis; 2)
propose or support the existence of a new molecular subtype;
3) alert investigators to be aware of potential confounding in
association studies; and 4) suggest surrogate markers in
clinical or research settings [27].
Materials and Methods
Study Group
We used the databases of two large prospective cohort
studies: the Nurses’ Health Study (N = 121,700 women
followed since 1976) [28] and the Health Professionals
Follow-Up Study (N = 51,500 men followed since 1986) [29].
Informed consent was obtained from all participants before
inclusion in the cohorts. A subset of the cohort participants
developed colorectal cancers during prospective follow-up.
Thus, these colorectal cancers represented population-
based, relatively unbiased samples (compared to retrospec-
tive or single-hospital–based samples). Previous studies on
the cohorts have described baseline characteristics of cohort
participants and incident colorectal cancer cases, and con-
firmed that our colorectal cancer cases were well-represented
as a population-based sample [28,29]. We collected paraffin-
embedded tissue blocks from hospitals where cohort partic-
ipants with colorectal cancers had undergone resections of
primary tumors. We excluded cases if adequate paraffin-
embedded tumor tissue was not available at the time of the
study. As a result, a total of 902 colorectal cancer cases
(405 from men’s cohort and 497 from women’s cohort) were
included. Among our cohort studies, there was no significant
difference in demographic features between cases with tissue
available and those without available tissue [30]. Many of the
cases have been previously characterized for status of CIMP,
MSI, KRAS, and BRAF [23]. However, no tumor has been
examined for IGFBP3 methylation in our previous studies.
Tissue collection and analyses were approved by the Dana-
Farber/Harvard Cancer Center and Brigham and Women’s
Hospital Institutional Review Boards.
Histopathologic Evaluations
Hematoxylin and eosin (H&E)–stained tissue sections
were examined under a light microscope by one of the in-
vestigators (S.O.) blinded from clinical and other laboratory
data as previously described [22]. The following eight fea-
tures were evaluated: 1) the presence and extent of extra-
cellular mucin were categorized as negative (no mucin),
< 50%, or z50% of the tumor volume; 2) the presence and
extent of signet ring cells were categorized as negative
(no signet ring cells), < 50%, or z 50% of the tumor volume;
3) degree of tumor differentiation was categorized as well/
moderate (z 50% gland formation) versus poor (< 50% gland
formation); 4) to 6) the degree of Crohn’s-like lymphoid re-
action (defined as transmural lymphoid aggregates), the
degree of a peritumoral lymphocytic reaction (defined as a
discrete lymphoid infiltrate surrounding tumor cell nests), and
the degree of tumor-infiltrating lymphocytes were graded as
absent/mild versus moderate/severe; 7) the extent of extra-
glandular tumor necrosis was graded as < 20% vs z 20%;
and 8) the type of tumor border was categorized as circum-
scribed versus infiltrative.
Genomic DNA Extraction and Whole Genome Amplification
Genomic DNA was extracted from dissected tumor tissue
sections using QIAmp DNA Mini Kit (Qiagen, Valencia, CA)
as previously described [31]. Normal DNAwas obtained from
colonic tissue at resection margins. Whole genome amplifi-
cation of genomic DNA was performed by polymerase chain
reaction (PCR) using random 15-mer primers for subsequent
MSI and loss of heterozygosity (LOH) analyses and KRAS
and BRAF sequencing [31]. Previous studies by us and
others showed that whole genome amplification did not
significantly affect subsequent genetic analysis [31,32].
Analyses for MSI and 18q LOH
Methods to analyze for MSI and TGFBR2 mutation have
been previously described [25,33]. In addition to the recom-
mended MSI panel consisting of D2S123, D5S346, D17S250,
BAT25, and BAT26 [34], we also used BAT40, D18S55,
D18S56, D18S67, and D18S487 (i.e., 10-marker panel) [33].
A high degree of MSI (MSI-H) was defined as the presence
of instability in z 30% of the markers. A low degree of MSI
(MSI-L) was defined as the presence of instability in < 30% of
the markers, and microsatellite stable (MSS) tumors were de-
fined as tumors without an unstable marker. PCR primers for
BAX mononucleotide repeat were: BAX-F, FAM–5V–atc cag
gat cga gca ggg cg–3V; BAX-R, 5V–act cgc tca gct tct tgg tg–3V.
PCR cycles consisted of initial denaturing at 94jC for 2 min-
utes, followed by 45 cycles of 94jC for 30 seconds, 55jC for
30 seconds, and 72jC for 30 seconds; and a final extension at
72jC for 2 minutes. PCR products were analyzed by ABI 3730
(Applied Biosystems, Foster City, CA). The presence of a peak
at an altered size in tumor DNA compared to normal DNA was
interpreted as positivity for BAX mutation.
For 18q LOHanalysis usingmicrosatellitemarkers D18S55,
D18S56, D18S67, and D18S487, we duplicated PCR reaction
and electrophoresis in each sample to exclude allele dropouts
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of one of two alleles [33]. LOH at each locus was defined as
40% or greater reduction of one of two allele peaks in tumor
DNA relative to normal DNA. Overall 18q LOH positivity was
defined as the presence of one or more markers with LOH,
and overall 18q LOH negativity as the presence of two or
more informative markers and the absence of LOH in all
informative markers.
Sequencing of KRAS and BRAF
Methods of PCR and sequencing targeted for KRAS co-
dons 12 and 13, and BRAF codon 600 have been previously
described [31,35]. Pyrosequecing was performed using the
PSQ96 HS System (Biotage AB and Biosystems, Uppsala,
Sweden) according to the manufacturer’s instructions.
Real-Time PCR (MethyLight) for Quantitative DNA
Methylation Analysis
Sodium bisulfite treatment on genomic DNA was per-
formed as previously described [36]. Real-time PCR to
measure DNA methylation (MethyLight) was performed as
previously described [37]. Using ABI 7300 (Applied Biosys-
tems), we examined IGFBP3 promoter and eight other CIMP-
specific promoters [calcium channel, voltage-dependent, T type
alpha-1G subunit (CACNA1G), cyclin-dependent kinase inhib-
itor 2A (CDKN2A) (p16), cellular retinoic acid binding protein 1
(CRABP1), insulin-like growth factor 2 (IGF2), MLH1, neuro-
genin1 (NEUROG1), runt-related transcription factor3 (RUNX3),
and suppressor of cytokine signaling 1 (SOCS1)] [20,24]. We
have shown that these eight markers are sensitive and spe-
cific markers for CIMP-high [23]. The collagen 2A1 gene
(COL2A1) was used to normalize for the amount of input
bisulfite-converted DNA [36]. The primers and probe for
IGFBP3 were (bisulfite-converted nucleotides are in italics):
IGFBP3-F, 5V–GT T TCG GGC GTG AGT ACG A–3V (Gen-
Bank No. M35878, nucleotides 1692–1710); IGFBP3-R, 5V–
GAA TCG ACG CAA ACA CGA CTA C–3V (GenBank No.
M35878, nucleotides 1789–1810); and IGFBP3-probe,
6FAM–5V–TCG GT T GT T TAG GGC GAA GTA CGG G–
3V–BHQ-1 (GenBank No. M35878, nucleotides 1760–1784)
[38]. Other primers and probes were previously described
[24]. The PCR condition was as follows: initial denaturation
at 95jC for 10 minutes followed by 45 cycles at 95jC for
15 seconds and 60jC for 1 minute. A standard curve was
made for each PCR plate by duplicated PCR amplifications
for COL2A1 on bisulfite-converted human genomic DNA at
four different concentrations (in a 5-fold dilution series). The
percentage of methylated reference (PMR; i.e., degree of
methylation) at a specific locus was calculated by dividing
the GENE/COL2A1 ratio of template amounts in a sample
by the GENE/COL2A1 ratio of template amounts in SssI-
treated human genomic DNA (presumably fully methylated)
and multiplying this value by 100 [37]. A PMR cutoff value of
4 (except for 6 in CRABP1 and IGF2) was based on pre-
viously validated data [36]. Precision and performance char-
acteristics of bisulfite conversion and subsequent MethyLight
assays have been previously evaluated and the assays have
been validated [36]. CIMP-high was defined as the presence
of z 6 of 8 methylated promoters, CIMP-low as 1 to 5 of
8 methylated promoters, and CIMP-0 as the absence (0 of 8)
of methylated promoters, according to the previously estab-
lished criteria [23].
Tissue Microarrays (TMAs) and Immunohistochemistry for
p53 and p21 (CDKN1A)
Tissue microarrays were constructed as previously de-
scribed [39]. TMAs were constructed using the Automated
Arrayer (Beecher Instruments, Sun Prairie, WI). Briefly, two
0.6-mm tissue cores each from a tumor and normal colonic
mucosa were placed in each TMA block. Each TMA block will
have a total of approximately 400 cores (100 cases). We
examined two to four tumor tissue cores for each marker. A
previous validation study have shown that examining two
TMA cores can yield comparable results to examining whole
tissue sections in more than 95% of cases [40]. We exam-
ined whole tissue sections for p21 in all cases, and for p53
in cases for which no tissue block was available for TMAs
or results were equivocal in TMAs. Immunohistochemistry
for p53 and p21 was performed as previously described
[41,42]. p53 positivity was defined as 50% or more of tumor
cells with unequivocal strong nuclear staining, as this high
threshold has been shown to improve specificity [43]. p21
loss was defined as less than 5% of tumor cells with nuclear
staining. Appropriate positive and negative controls were in-
cluded in each run of immunohistochemistry. All immuno-
histochemically stained slides were interpreted by one of
the investigators (S.O.) blinded from any other clinical and
laboratory data.
Statistical Analysis
In the statistical analysis, chi-square test (or Fisher’s
exact test when the number in any category was less than
10) was performed for categorical data, and kappa coeffi-
cients were calculated to determine the degree of agreement
between two observers, using SAS program (Version 9.1,
SAS Institute, Cary, NC). All P values were two-sided and
statistical significance was set at P V .05.
Results
IGFBP3 Promoter Methylation Is Correlated with CIMP-High
Using MethyLight technology, we quantified DNA methyl-
ation in IGFBP3 and a panel of eight promoters (CACNA1G,
CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and
SOCS1) [23,24]. The latter eight promoters constitute a
sensitive and specific marker panel for CIMP [23]. Among
the 902 tumors, 258 (29%) were positive for IGFBP3 pro-
moter methylation. There was no significant difference in
the frequencies of IGFBP3 methylation between men (28%)
and women (30%). Sensitivity and specificity of IGFBP3
methylation for the diagnosis of CIMP-high (z 6 of 8 meth-
ylated promoters, not including IGFBP3) were 60% and
77%, respectively (Table 1). Thus, IGFBP3 methylation
was not an excellent marker for CIMP-high, but was still pos-
itively correlated with CIMP-high (P < .0001). Because 5/8
methylated tumors showed borderline features between
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CIMP-high and CIMP-low [23], we excluded those tumors
from further analyses.
We also quantified IGFBP3methylation in normal colon tis-
sue in four IGFBP3-methylated tumor cases and 12 IGFBP3-
unmethylated tumor cases. Only one normal sample among
the four IGFBP3-methylated tumor cases showed IGFBP3
methylation, and all of the other normal samples showed un-
methylated IGFBP3.
Inverse Relationship between IGFBP3 and MSI in
CIMP-High Tumors
Becausemolecular classification based onMSI and CIMP
status is increasingly important [26], we stratified tumors into
four categories according to MSI and CIMP status (Figure 1).
Within CIMP-high tumors, the frequency of IGFBP3 methyl-
ation was significantly higher in MSI-L/MSS CIMP-high tu-
mors (85%) than MSI-H CIMP-high tumors (49%, P < .0001),
indicating an inverse relationship between IGFBP3 methyl-
ation and MSI in CIMP-high tumors. CIMP-low/0 tumors
showed low frequencies (17–22%) of IGFBP3 methylation
regardless of MSI status.
IGFBP3 Methylation, CIMP, and Pathologic Features
Because IGFBP3methylation is positively correlated with
CIMP-high, we stratified tumors according to IGFBP3 and
CIMP status in subsequent analyses (as in Tables 2 and 3).
Then, we could examine the effect of IGFBP3methylation on
various pathologic and molecular features independent of
CIMP status.
Table 2 summarizes the relations between IGFBP3meth-
ylation and pathologic features in colorectal cancer. Proximal
tumor location, poor differentiation, mucinous features, tumor-
infiltrating lymphocytes, and Crohn’s-like reaction were signif-
icantly associated with IGFBP3 methylation in all cases, but
no significant correlations persisted after tumors were strati-
fied by CIMP status. These findings indicate that those
features are associated primarily with CIMP, but not directly
with IGFBP3 methylation.
IGFBP3 Methylation, CIMP, and Other Molecular Features
Table 3 summarizes the relations between IGFBP3meth-
ylation and other molecular features in colorectal cancer.
Whereas MSI and IGFBP3 were not significantly correlated in
all cases and CIMP-low/0 cases, MSI and IGFBP3methylation
were inversely correlated in CIMP-high tumors (P < .0001).
Interestingly, IGFBP3 methylation and TGFBR2 mutation
were inversely correlated (P = .02) in MSI-H CIMP-low/0
tumors, and IGFBP3 methylation and BAX mutation were
positively correlated (P = .02) in MSI-H CIMP-high tumors
(Table 3). These results may suggest possible interactions
between the pathways related to these molecules (Figure 2).
BRAF mutation, 18q LOH, and p21 loss were correlated
with IGFBP3methylation in all cases, but the relations did not
persist after tumors were stratified by CIMP status.
Relationship between IGFBP3 Methylation and MSI
according to p53 or p21 Status
Because IGFBP3 is one of the downstream effectors of
the p53 pathway (Figure 2), we examined the interrelation-
ship between MSI, IGFBP3, and p53 (Figure 3). The inverse
relationship between MSI and IGFBP3methylation (in CIMP-
high tumors) persisted in p53-negative tumors (P < .0001),
but not in p53-positive tumors. These results suggest that
IGFBP3 methylation may be more important in TP53 wild-
type tumors than in TP53-mutated tumors, which may have
already downregulated IGFBP3.
We also examined the interrelationship between MSI,
IGFBP3, and p21, one of the downstream effectors of p53
(Figure 4). The inverse relationship betweenMSI and IGFBP3
methylation persisted regardless of p21 status, suggesting
that p21 and IGFBP3 functions were not directly linked.
Discussion
We conducted this study to examine IGFBP3 methylation in
colorectal cancer, particularly in relation to MSI, CIMP, and
p53. Molecular classification of colorectal cancer according
to MSI and CIMP is increasingly important [26], because MSI
Table 1. Sensitivity and Specificity of IGFBP3 Methylation for the Diagnosis of CIMP-High.
CIMP-High (z 6/8 Methylated Promoters) Non–CIMP-High (V5/8 Methylated Promoters) Total
IGFBP3 Methylation Positive 79 (sensitivity 60%*) 179 (23%) 258
Negative 53 (40%) 591 (specificity 77%y) 644
Total 132 770 902
*Sensitivity is defined as the number of IGFBP3-positive CIMP-high cases divided by the number of all CIMP-high cases.
ySpecificity is defined as the number of IGFBP3-negative non–CIMP-high cases divided by the number of all non–CIMP-high cases.
CIMP, CpG island methylator phenotype.
Figure 1. Frequency of IGFBP3 methylation in four MSI/CIMP subtypes of
colorectal cancer. CIMP, CpG island methylator phenotype; MSI, microsat-
ellite instability; MSS, microsatellite stable.
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and CIMP represent global genomic and epigenomic phe-
nomena, respectively, in tumor cells, and largely determine
clinical, pathologic, and molecular features of colorectal
cancer. We have found that IGFBP3 methylation is inversely
associated with MSI in CIMP-high tumors, but not in CIMP-
low/0 tumors, and that this inverse relationship is limited to
p53-negative tumors, but not p53-positive tumors. Our find-
ings imply the complex interrelationship between genomic/
epigenomic phenomena (such as MSI and CIMP) and single
molecular events, IGFBP3methylation and p53 alteration, in
colorectal cancer.
Transcriptional inactivation of tumor suppressor genes by
promoter CpG island methylation is an important mechanism
in human carcinogenesis [14]. Epigenetic aberrations have
been reported in various tumor-related genes [14,44–47].
For quantitative DNA methylation analysis, we used Methy-
Light, which is robust and can reproducibly differentiate low-
level methylation from high-level methylation [36,48,49]. Our
resource of a large number of colorectal cancers, derived
from two large prospective cohorts (relatively unbiased sam-
ples compared to retrospective or single-hospital–based sam-
ples), has enabled us to precisely estimate the frequency of
colorectal cancers with a specific molecular feature (e.g.,
IGFBP3methylation, MSI-H, and so forth). The large number
of samples has also provided a sufficient power to accurately
estimate the frequency of IGFBP3 methylation in rare tumor
subtypes, such as MSI-L/MSS CIMP-high, CIMP-high p53-
positive, and so forth.
IGFBP3 is one of the important downstream effectors of
the p53 pathway [8,10], and is also known to interact with
the TGF-b pathway [11–13] (Figure 2). Thus, we have exam-
ined the interrelationship between IGFBP3 methylation, p53
positivity, and MSI, and found that the inverse correlation
between IGFBP3 methylation and MSI in CIMP-high tumors
Table 2. Frequencies of Specific Clinical and Pathologic Features in Colorectal Cancer according to IGFBP3 Methylation and CIMP Status.
Clinical and Pathologic Features N All Cases P CIMP-High P CIMP-Low/0 P
IGFBP3 Methylation IGFBP3 Methylation IGFBP3 Methylation
(+) () (+) () (+) ()
All Cases 902 259 643 80 53 161 582
Men 405 112 293 29 14 74 275
Women 497 147 350 51 39 87 307
Tumor Location
Total Examined 522 148 374 48 33 87 334
Proximal 248 97 (66%) 151 (40%) < .0001 44 (92%) 31 (94%) 42 (48%) 117 (35%) .02
Distal 274 51 (34%) 223 (60%) 4 (8.3%) 2 (6.1%) 45 (52%) 217 (65%)
Tumor Differentiation
Total Examined 885 255 630 80 53 158 568
Well/Moderate 802 221 (87%) 581 (92%) .01 57 (71%) 36 (68%) 148 (94%) 538 (95%)
Poor 83 34 (13%) 49 (7.8%) 23 (29%) 17 (32%) 10 (6.3%) 30 (5.3%)
Mucinous/Signet Ring Cell Features
Total Examined 782 228 554 76 49 136 497
Nonmucinous Carcinoma 471 100 (44%) 371 (67%) < .0001 26 (34%) 20 (41%) 69 (51%) 346 (70%) < .0001
Mucinous
1–100% 311 128 (56%) 183 (33%) 50 (66%) 29 (59%) 67 (49%) 151 (30%)
1–49% 191 78 (34%) 113 (20%) 24 (32%) 12 (24%) 45 (33%) 100 (20%)
z 50% 120 50 (22%) 70 (13%) 26 (34%) 17 (35%) 22 (16%) 51 (10%)
Nonsignet Ring Cell Carcinoma 721 207 (91%) 514 (93%) 62 (82%) 39 (80%) 130 (96%) 468 (94%)
Signet Ring Cells
1–100% 61 21 (9.2%) 40 (7.2%) 14 (18%) 10 (20%) 6 (4.4%) 29 (5.8%)
1–49% 46 17 (7.5%) 29 (5.2%) 12 (16%) 9 (18%) 4 (2.9%) 19 (3.8%)
z 50% 15 4 (1.8%) 11 (2.0%) 2 (2.6%) 1 (2.0%) 2 (1.5%) 10 (2.0%)
Tumor-Infiltrating Lymphocytes
Total Examined 877 251 626 79 51 155 566
Absent/Mild 778 210 (84%) 568 (91%) .003 50 (63%) 39 (57%) 145 (94%) 533 (94%)
Moderate/Severe 99 41 (16%) 58 (9.3%) 29 (37%) 22 (43%) 10 (6.5%) 33 (5.8%)
Crohn’s-Like Reaction
Total Examined 674 198 476 58 41 124 428
Absent/Mild 611 172 (87%) 439 (92%) .03 38 (66%) 28 (68%) 120 (97%) 404 (94%)
Moderate/Severe 63 26 (13%) 37 (7.7%) 20 (34%) 13 (32%) 4 (3.2%) 24 (5.6%)
Peritumoral Lymphocytic Reaction
Total Examined 879 275 604 76 51 182 541
Absent/Mild 782 241 (88%) 541 (90%) 47 (63%) 39 (57%) 172 (95%) 493 (91%)
Moderate/Severe 97 34 (12%) 63 (10%) 29 (37%) 22 (43%) 10 (5.5%) 48 (8.9%)
Tumor Border
Total Examined 726 219 507 69 43 136 455
Circumscribed 262 74 (34%) 188 (37%) 26 (38%) 16 (37%) 45 (33%) 167 (37%)
Infiltrative 464 145 (66%) 319 (63%) 43 (62%) 27 (63%) 91 (67%) 288 (63%)
Extraglandular Necrosis
Total Examined 896 259 637 80 52 161 576
< 20% 802 230 (89%) 572 (90%) 64 (80%) 37 (71%) 149 (93%) 526 (91%)
z 20% 94 29 (11%) 65 (10%) 16 (20%) 15 (29%) 12 (7.5%) 50 (8.7%)
Only significant P values are described.
CIMP, CpG island methylator phenotype.
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is limited to p53-negative tumors. Thus, IGFBP3methylation
may be important in TP53 wild-type tumors, whereas TP53-
mutated tumors may have already downregulated IGFBP3
and IGFBP3methylation may be less relevant. We have also
found an inverse correlation between IGFBP3 methylation
and TGFBR2 mutation in MSI-H CIMP-low/0 tumors, as well
as a positive correlation between IGFBP3 methylation and
BAX mutation in MSI-H CIMP-high tumors. These complex
correlations suggest the intricate relationship between global
genomic/epigenomic phenomena (such as MSI and CIMP),
these single molecular events (such as IGFBP3methylation,
TP53mutation, TGFBR2mutation, and so forth), and the re-
lated pathways in colorectal cancer.
In summary, IGFBP3 promoter methylation in colorectal
cancer is inversely associated with MSI in CIMP-high colo-
Table 3. Frequencies of Specific Molecular Features in Colorectal Cancer according to IGFBP3 Methylation and CIMP Status.
Molecular Features N All Cases P CIMP-High P CIMP-Low/0 P
IGFBP3 Methylation IGFBP3 Methylation IGFBP3 Methylation
(+) () (+) () (+) ()
MSI
Total Examined 874 255 619 79 52 158 558
MSI-H 127 50 (20%) 77 (12%) 44 (56%) 46 (88%) < .0001 6 (3.8%) 30 (5.4%)
MSI-L/MSS 747 205 (80%) 542 (88%) 35 (44%) 6 (12%) 152 (96%) 528 (95%)
KRAS
Total Examined 860 250 610 77 51 155 550
Mutant 313 102 (41%) 211 (35%) 14 (18%) 4 (7.8%) 79 (51%) 204 (37%) .002
Wild-Type 547 148 (59%) 399 (65%) 53 (82%) 47 (92%) 76 (49%) 346 (63%)
BRAF
Total Examined 860 250 610 77 51 155 550
Mutant 112 59 (24%) 53 (8.7%) < .0001 45 (58%) 32 (63%) 8 (5.2%) 18 (3.3%)
Wild-Type 748 191 (76%) 557 (91%) 32 (42%) 19 (37%) 147 (95%) 532 (97%)
18q LOH
Total Examined (Only Non–MSI-H Tumors) 540 151 389 29 5 107 377
(+) 353 85 (56%) 268 (69%) .006 18 (62%) 2 (40%) 63 (59%) 261 (69%) .04
() 187 66 (44%) 121 (31%) 11 (38%) 3 (60%) 44 (41%) 116 (31%)
p53*
Total Examined 891 257 634 80 53 159 573
(+) 386 109 (42%) 277 (44%) 21 (26%) 9 (17%) 81 (51%) 263 (46%)
() 505 148 (58%) 357 (56%) 59 (74%) 44 (83%) 78 (49%) 310 (54%)
p21*
Total Examined 864 251 613 79 50 155 555
Loss 508 124 (49%) 384 (63%) .0003 22 (28%) 9 (18%) 92 (59%) 371 (67%)
(+) 356 127 (51%) 229 (37%) 57 (72%) 41 (82%) 63 (41%) 184 (33%)
TGFBR2 Mutation
Total Examined (Only MSI-H Tumors) 127 50 77 44 46 6 30
(+) 94 37 (74%) 57 (74%) 37 (84%) 39 (85%) 0 18 (60%) .02
() 33 13 (26%) 20 (26%) 7 (16%) 7 (15%) 6 (100%) 12 (40%)
BAX Mutation
Total Examined (Only MSI-H Tumors) 126 50 76 44 45 6 30
(+) 32 18 (36%) 14 (18%) .03 18 (41%) 8 (18%) .02 0 5 (17%)
() 94 32 (64%) 62 (82%) 26 (59%) 37 (82%) 6 (100%) 25 (83%)
*p53 and p21 status was determined by immunohistochemistry.
Only significant P values are described.
CIMP, CpG island methylator phenotype; LOH, loss of heterozygosity; MSI, microsatellite instability.
Figure 2. The p53 pathway and IGFBP3.
Figure 3. Frequency of IGFBP3 methylation in CIMP-high tumors according
to p53 and MSI status. Note that the inverse relationship between MSI and
IGFBP3methylation is present in p53-negative tumors, but not in p53-positive
tumors. CIMP, CpG island methylator phenotype; MSI, microsatellite
instability; MSS, microsatellite stable; NS, not significant.
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rectal cancer, and this inverse correlation is limited to p53-
negative tumors. Further studies are necessary to elucidate
the exact pathogenic role of IGFBP3 promoter methylation in
colorectal cancer.
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